Shares of Analogic Corp. (NASDAQ:ALOG) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $91.24 and last traded at $90.18, with a volume of 12,744 shares. The stock had previously closed at $88.90.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Analogic Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Brean Capital reissued a “buy” rating on shares of Analogic Corp. in a research report on Thursday, June 2nd. Finally, TheStreet raised Analogic Corp. from a “hold” rating to a “buy” rating in a research report on Wednesday, June 8th.

The stock has a market capitalization of $1.13 billion and a P/E ratio of 79.82. The firm’s 50-day moving average is $85.85 and its 200-day moving average is $80.87.

In other Analogic Corp. news, CEO James W. Green sold 500 shares of the business’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $88.96, for a total transaction of $44,480.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Shalabh Chandra sold 2,650 shares of the business’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $90.00, for a total value of $238,500.00. Following the sale, the insider now owns 5,967 shares in the company, valued at $537,030. The disclosure for this sale can be found here.

Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies to advance the practice of medicine and save lives. The Company operates through three business segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.